PL1873166T3 - Ulepszone dimery sgp 130Fc - Google Patents

Ulepszone dimery sgp 130Fc

Info

Publication number
PL1873166T3
PL1873166T3 PL06013668T PL06013668T PL1873166T3 PL 1873166 T3 PL1873166 T3 PL 1873166T3 PL 06013668 T PL06013668 T PL 06013668T PL 06013668 T PL06013668 T PL 06013668T PL 1873166 T3 PL1873166 T3 PL 1873166T3
Authority
PL
Poland
Prior art keywords
dimers
sgp
improved
dimer
molecules
Prior art date
Application number
PL06013668T
Other languages
English (en)
Inventor
Georg Wätzig
Dirk Seegert
Original Assignee
Conaris Res Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Institute Ag filed Critical Conaris Res Institute Ag
Publication of PL1873166T3 publication Critical patent/PL1873166T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL06013668T 2006-06-30 2006-06-30 Ulepszone dimery sgp 130Fc PL1873166T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06013668A EP1873166B1 (en) 2006-06-30 2006-06-30 Improved sgp 130Fc dimers

Publications (1)

Publication Number Publication Date
PL1873166T3 true PL1873166T3 (pl) 2011-03-31

Family

ID=37654867

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06013668T PL1873166T3 (pl) 2006-06-30 2006-06-30 Ulepszone dimery sgp 130Fc

Country Status (21)

Country Link
US (3) US8895012B2 (pl)
EP (1) EP1873166B1 (pl)
JP (1) JP5417171B2 (pl)
KR (1) KR101474817B1 (pl)
CN (1) CN101484472B (pl)
AT (1) ATE480568T1 (pl)
AU (1) AU2007263939B2 (pl)
BR (1) BRPI0713063B8 (pl)
CA (1) CA2656440C (pl)
CY (1) CY1110973T1 (pl)
DE (1) DE602006016765D1 (pl)
DK (1) DK1873166T3 (pl)
EA (1) EA015620B1 (pl)
ES (1) ES2352561T3 (pl)
HR (1) HRP20100663T1 (pl)
PL (1) PL1873166T3 (pl)
PT (1) PT1873166E (pl)
RS (1) RS51544B (pl)
SI (1) SI1873166T1 (pl)
UA (1) UA95636C2 (pl)
WO (1) WO2008000516A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480568T1 (de) 2006-06-30 2010-09-15 Conaris Res Inst Ag Verbesserte sgp 130fc dimere
CA2690825C (en) 2007-05-11 2019-02-12 Altor Bioscience Corporation Fusion molecules and il-15 variants
EP2050759A1 (en) * 2007-10-19 2009-04-22 CONARIS research institute AG Soluble gp 130 muteins with improved binding activity
KR20140020228A (ko) * 2010-09-21 2014-02-18 알토 바이오사이언스 코포레이션 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
EP3139660B1 (en) * 2013-09-20 2021-01-20 Intel Corporation Ap location query
EP3673915A1 (en) 2014-06-30 2020-07-01 Altor BioScience Corporation Il-15-based molecules and methods of use thereof
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
MA41116A (fr) * 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
DK3226888T3 (da) * 2014-12-01 2021-07-12 Ferring Bv Administration af en selektiv inhibitor af il-6-trans-signalering
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455241B1 (en) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Method of cleaning and/or sanitizing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3529263A4 (en) 2016-10-21 2020-07-08 Altor BioScience Corporation MULTIMERIC MOLECULES BASED ON IL-15
CN108593912A (zh) * 2018-04-09 2018-09-28 北京大学深圳研究生院 一种可溶性cd38浓度的检测方法
CN108318689A (zh) * 2018-04-09 2018-07-24 北京大学深圳研究生院 一种多发性骨髓瘤的诊断方法
BR112022025166A2 (pt) 2020-06-10 2022-12-27 Ferring Bv Composto farmacêutico para o tratamento de doença cardiovascular aterosclerótica
WO2022139580A1 (en) 2020-12-22 2022-06-30 Ferring B.V. Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases
CN118043639A (zh) * 2021-09-01 2024-05-14 泰利斯制药(创新)有限公司 聚集体分离方法
WO2024011946A1 (en) * 2022-07-12 2024-01-18 I-Mab Biopharma (Hangzhou) Co., Ltd Polypeptide dimers for the treatment of systemic sclerosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
PL199659B1 (pl) * 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
DE19941897B4 (de) 1999-09-02 2006-06-14 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen
ES2269366T3 (es) * 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
DE60037648T2 (de) * 2000-04-21 2010-06-17 Conaris Research Institute Ag Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten
KR20030097876A (ko) 2001-05-21 2003-12-31 넥타르 테라퓨틱스 화학적으로 개질된 인슐린의 폐 투여
US7507412B2 (en) * 2001-07-18 2009-03-24 Merck Patent Gmbh Glycoprotein VI fusion proteins
AU2002356511A1 (en) * 2001-07-30 2003-04-01 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
CA2526169A1 (en) * 2003-06-12 2004-12-23 Eli Lilly And Company Fusion proteins
EP1491554A1 (en) 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
PT1630232E (pt) 2004-08-27 2008-10-02 Conaris Res Inst Ag Sequências de nucleótidos optimizadas que codificam sgp130
EP1801121A1 (en) 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
ATE480568T1 (de) 2006-06-30 2010-09-15 Conaris Res Inst Ag Verbesserte sgp 130fc dimere

Also Published As

Publication number Publication date
EP1873166B1 (en) 2010-09-08
ES2352561T3 (es) 2011-02-21
US20100028367A1 (en) 2010-02-04
US9573989B2 (en) 2017-02-21
UA95636C2 (en) 2011-08-25
CN101484472A (zh) 2009-07-15
HRP20100663T1 (hr) 2011-01-31
WO2008000516A3 (en) 2008-03-27
WO2008000516B1 (en) 2008-05-08
AU2007263939B2 (en) 2011-11-24
JP2009540843A (ja) 2009-11-26
WO2008000516A2 (en) 2008-01-03
CY1110973T1 (el) 2015-06-11
AU2007263939A1 (en) 2008-01-03
CN101484472B (zh) 2013-07-24
CA2656440C (en) 2018-10-02
US9034817B2 (en) 2015-05-19
EA200802396A1 (ru) 2009-06-30
EP1873166A1 (en) 2008-01-02
US20140178378A1 (en) 2014-06-26
DK1873166T3 (da) 2010-12-20
KR101474817B1 (ko) 2014-12-22
BRPI0713063B1 (pt) 2019-10-08
SI1873166T1 (sl) 2011-01-31
US8895012B2 (en) 2014-11-25
PT1873166E (pt) 2010-12-09
RS51544B (en) 2011-06-30
EA015620B1 (ru) 2011-10-31
US20150361157A1 (en) 2015-12-17
KR20090037898A (ko) 2009-04-16
CA2656440A1 (en) 2008-01-03
DE602006016765D1 (de) 2010-10-21
BRPI0713063B8 (pt) 2021-05-25
JP5417171B2 (ja) 2014-02-12
BRPI0713063A2 (pt) 2012-04-17
ATE480568T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
PL1873166T3 (pl) Ulepszone dimery sgp 130Fc
NZ592509A (en) HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
DK1347730T3 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
ATE294817T1 (de) Concatamere immunadhäsion
PE20091405A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CA2648109A1 (en) Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine
WO2005001038A3 (en) Recombinant anti-cd30 antibodies and uses thereof
EA200700213A1 (ru) Терапевтические композиции с нейротоксином ботулина
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
UA106869C2 (uk) Поліпептид ace2
WO2006001023A3 (en) Chimeric proteins and uses thereof
ATE485386T1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
HK1121468A1 (en) Synthetic mecp2 sequence for protein substitution therapy
BRPI0720879B8 (pt) microvesícula derivada de levedura carreadora de fator tissular (tf), composição e composição farmacêutica que a compreende e processos para a sua fabricação
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
WO2012078761A3 (en) Dimeric molecular complexes with free cysteine residues and conjugates thereof
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
WO2002048180A3 (de) Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels
WO2008003707A3 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
WO2008062158A3 (en) Polypeptide monomers and dimers containing mutated ilt
ATE492637T1 (de) An die lck-sh3 und hck-sh3 domäne bindende peptide
BRPI0403173A (pt) polipeptìdeo, molécula de ácido nucleico, vetor, método para preparar um polipeptìdeo, célula, uso do polipeptìdeo e/ou ácido nucleico e/ou do vetor, composição farmacêutica, e, método de tratamento de um paciente humano ou animal